Full-Time
Confirmed live in the last 24 hours
AI-driven healthcare data analysis platform
$100k - $140kAnnually
Senior, Expert
No H1B Sponsorship
Remote in USA
Candidates must be residing in the U.S. Salary ranges are provided for New York, California, and Illinois.
You match the following Tempus's candidate preferences
Employers are more likely to interview you if you match these preferences:
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$894.9M
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
What You Should Know:– Tempus AI, a provider of AI-powered precision medicine launches olivia, an innovative personal health concierge app designed to revolutionize how patients manage their health information.– olivia brings together a patient’s health data from various sources, leverages AI to provide actionable insights, and empowers patients to take control of their health journey.Centralizing Health DataOlivia serves as a central hub for all of a patient’s health information. Patients can connect to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. This comprehensive data integration allows patients to access a complete and accurate picture of their health history.Actionable Insights Through AIolivia’s AI-enabled capabilities transform raw data into actionable insights. Patients can ask questions about their records, summarize their health information, and receive personalized responses based on their data. For example, a patient can ask, “Summarize my health status,” and olivia will provide a clear, concise summary of their health information.Empowering Patients to Take Control of Their HealthIn addition to centralizing data and providing actionable insights, olivia offers several other features to enhance the patient experience:Smart Profile Summary: olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team.olivia synthesizes a patient’s data into an AI-generated smart profile, detailing information such as clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface.olivia provides patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface
Tempus announces the national launch of FDA-approved xT CDx test.
Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.
Beta Bionics, maker of the iLet Bionic Pancreas, filed for an IPO to be listed on Nasdaq as "BBNX." The company aims to use the proceeds to expand sales, manufacturing, and develop new features. In 2024, Beta Bionics reported $44.7 million in revenue and a net loss of $36.6 million for the first nine months. The iLet pump, cleared by the FDA in 2023, is designed for Type 1 diabetes patients and requires less user input. The company plans to expand its use for Type 2 diabetes and develop a patch pump version.
Tempus to present at 43rd Annual J.P. Morgan Healthcare Conference.
Tidal Investments LLC makes new $7.63 million investment in Tempus AI, Inc. (NASDAQ:TEM).
Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR(R) platform through Molecular Profiling Integration (MPI).
Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm using artificial intelligence for precision medicine.Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.
Tempus announces the clinical launch of its Immune Profile Score algorithmic test.
Tempus announces collaboration with JW Pharmaceutical to apply real-world data and biological modeling to enhance early research and development.